Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

To contribute published user compound and/or population files, upload your files here: Upload Model Files

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

|<

<

6

7

8

9

10

11

12

13

14

15

16

17

18

19

>

>|

Found 108 Matches

Hydroxychloroquine_V18R1_PekingUniversityThirdHospital_20200323

The HCQ file was developed by Peking University Third Hospital and kindly shared on our Members Area. Please cite the original reference in which the file was presented (see link to publication) and please share your simulation results ASAP. Considering the current public health situation, we are happy to coordinate the simulation efforts around this PBPK model. The submitted compound file for HCQ is using first order absorption model, full-PBPK, Method 2. Perfusion limited lung model was developed. Additional organ was defined as lung and changed the tissue blood rate flow as 0.2. Clearance of HLM was estimated based on fm. It has been verified with a Caucasian healthy volunteer population library that was unmodified from the Sim-Healthy Volunteer library file. Please note a custom dosing for 5 days has been included in the file. https://pubmed.ncbi.nlm.nih.gov/32150618/

Propofol_RES_V18R1_Simcyp_20190529

Simcyp developed propofol compound file. Compound summary included. This was developed as a research file and its current status and limitations are outlined in the summary document.

Tizanidine_RES_V18R1_Simcyp_20190809

Simcyp developed tizanidine compound file. Compound summary included. This was developed as a research file and its current status and limitations are outlined in summary document.

Chlorpromazine

Brand Name(s) include: Thorazine, Largactil, Ormazine

Indication: Schizophrenia, manic-depression

Drug Class: Conventional anitpsychotic

Date Updated: March 2024

The model at-a-glance

  Absorption Model

  • First-Order, fa and ka predicted by Caco-2 data

  Volume of Distribution

  • Minimal (optimized to IV data)

  Route of Elimination

  • fmCYP3A4 = 80, fmCYP2D6 = 20

  Perpetrator DDI

  • Inhibition of CYP2D6

  Validation

  • Model performance was verified in healthy volunteers and psychiatric patients. Two clinical studies with IV administration (7 to 10 mg) and ten clinical studies with oral administration (25 to 200 mg) were used for model verification. Simulations for eight of eleven clinical studies with a reported AUC were within 2-fold of the observed value.
  • The fmCYP1A2 was verified through simulations of chlorpromazine in smokers and non-smokers. The fmCYP2D6­ was verified through simulations of chlorpromazine coadministered with and without quinidine.

  Limitations

  • Model was developed using 10 mg IV and 100 mg PO. Use of 7-10 mg IV dosing and oral doses of 100-200 mg were verified, but predictions of oral doses <100 mg PO are overestimated.
  • Model does not include P-gp efflux.
  • Model is not verified for use in perpetrator DDI simulations with CYP2D6 substrates.

 

|<

<

6

7

8

9

10

11

12

13

14

15

16

17

18

19

>

>|